"immunosuppression; polysaccharide vaccine; conjugated vaccine; pneumococci"@en . "RIV/60162694:G44__/13:43874765!RIV14-MO0-G44_____" . "CZ - \u010Cesk\u00E1 republika" . "O\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin pacient\u016F proti pneumokokov\u00FDm infekc\u00EDm"@cs . . . "RIV/60162694:G44__/13:43874765" . "O\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin pacient\u016F proti pneumokokov\u00FDm infekc\u00EDm"@cs . . "1"^^ . . "O\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin pacient\u016F proti pneumokokov\u00FDm infekc\u00EDm" . . "1"^^ . "The risk group vaccination against pneumococcal diseases"@en . . "The risk group vaccination against pneumococcal diseases"@en . "Chl\u00EDbek, Roman" . "1214-8911" . . "1" . . . . "Pneumokokov\u00E1 onemocn\u011Bn\u00ED pat\u0159\u00ED st\u00E1le mezi z\u00E1va\u017En\u00E1 onemocn\u011Bn\u00ED d\u011Btsk\u00E9 i dosp\u011Bl\u00E9 populace. P\u0159es dostupn\u00E9 o\u010Dkov\u00E1n\u00ED pat\u0159\u00ED st\u00E1le rizikov\u00E9 skupiny pacient\u016F mezi nejohro\u017Een\u011Bj\u0161\u00ED. V n\u011Bkter\u00FDch zem\u00EDch, kde pozoruj\u00ED nep\u0159\u00EDm\u00FD \u00FA\u010Dinek o\u010Dkov\u00E1n\u00ED d\u011Bt\u00ED na pokles incidence invazivn\u00EDch pneumokokov\u00FDch onemocn\u011Bn\u00ED u dosp\u011Bl\u00FDch, nepozoruj\u00ED tento pokles u rizikov\u00FDch skupin a imunokompromitovan\u00FDch. V \u010Cesk\u00E9 republice dosud nep\u0159\u00EDm\u00FD efekt nebyl zaznamen\u00E1n, proto o\u010Dkov\u00E1n\u00ED star\u0161\u00EDch dosp\u011Bl\u00FDch a pacient\u016F s imunosupres\u00ED \u010Di komorbiditami proti pneumokok\u016Fm m\u00E1 velik\u00FD v\u00FDznam. K dispozici jsou dva druhy vakc\u00EDn, konjugovan\u00E1 13valentn\u00ED a polysacharidov\u00E1 23valentn\u00ED. Ka\u017Ed\u00E1 z nich m\u00E1 sv\u00E9 v\u00FDhody a nev\u00FDhody. Jednou z cest, jak zv\u00FD\u0161it proo\u010Dkovanost pr\u00E1v\u011B rizikov\u00FDch skupin, je tvorba n\u00E1rodn\u00EDch doporu\u010Den\u00ED pro o\u010Dkuj\u00EDc\u00ED l\u00E9ka\u0159e. Proto vzniklo doporu\u010Den\u00ED \u010Cesk\u00E9 vakcinologick\u00E9 spole\u010Dnosti pro pneumokokovou vakcinaci v dosp\u011Blosti, pro aplikaci obou vakc\u00EDn. Pln\u00E9 vyu\u017Eit\u00ED o\u010Dkov\u00E1n\u00ED konjugovanou vakc\u00EDnou proti pneumokok\u016Fm v rizikov\u00FDch skupin\u00E1ch pacient\u016F lze o\u010Dek\u00E1vat po roz\u0161\u00ED\u0159en\u00ED v\u011Bkov\u00E9 indikace na prakticky v\u0161echny v\u011Bkov\u00E9 kategorie a potvrzen\u00ED \u00FA\u010Dinnosti v prevenci pneumoni\u00ED."@cs . "O\u010Dkov\u00E1n\u00ED rizikov\u00FDch skupin pacient\u016F proti pneumokokov\u00FDm infekc\u00EDm" . "Medical Tribune" . "Pneumokokov\u00E1 onemocn\u011Bn\u00ED pat\u0159\u00ED st\u00E1le mezi z\u00E1va\u017En\u00E1 onemocn\u011Bn\u00ED d\u011Btsk\u00E9 i dosp\u011Bl\u00E9 populace. P\u0159es dostupn\u00E9 o\u010Dkov\u00E1n\u00ED pat\u0159\u00ED st\u00E1le rizikov\u00E9 skupiny pacient\u016F mezi nejohro\u017Een\u011Bj\u0161\u00ED. V n\u011Bkter\u00FDch zem\u00EDch, kde pozoruj\u00ED nep\u0159\u00EDm\u00FD \u00FA\u010Dinek o\u010Dkov\u00E1n\u00ED d\u011Bt\u00ED na pokles incidence invazivn\u00EDch pneumokokov\u00FDch onemocn\u011Bn\u00ED u dosp\u011Bl\u00FDch, nepozoruj\u00ED tento pokles u rizikov\u00FDch skupin a imunokompromitovan\u00FDch. V \u010Cesk\u00E9 republice dosud nep\u0159\u00EDm\u00FD efekt nebyl zaznamen\u00E1n, proto o\u010Dkov\u00E1n\u00ED star\u0161\u00EDch dosp\u011Bl\u00FDch a pacient\u016F s imunosupres\u00ED \u010Di komorbiditami proti pneumokok\u016Fm m\u00E1 velik\u00FD v\u00FDznam. K dispozici jsou dva druhy vakc\u00EDn, konjugovan\u00E1 13valentn\u00ED a polysacharidov\u00E1 23valentn\u00ED. Ka\u017Ed\u00E1 z nich m\u00E1 sv\u00E9 v\u00FDhody a nev\u00FDhody. Jednou z cest, jak zv\u00FD\u0161it proo\u010Dkovanost pr\u00E1v\u011B rizikov\u00FDch skupin, je tvorba n\u00E1rodn\u00EDch doporu\u010Den\u00ED pro o\u010Dkuj\u00EDc\u00ED l\u00E9ka\u0159e. Proto vzniklo doporu\u010Den\u00ED \u010Cesk\u00E9 vakcinologick\u00E9 spole\u010Dnosti pro pneumokokovou vakcinaci v dosp\u011Blosti, pro aplikaci obou vakc\u00EDn. Pln\u00E9 vyu\u017Eit\u00ED o\u010Dkov\u00E1n\u00ED konjugovanou vakc\u00EDnou proti pneumokok\u016Fm v rizikov\u00FDch skupin\u00E1ch pacient\u016F lze o\u010Dek\u00E1vat po roz\u0161\u00ED\u0159en\u00ED v\u011Bkov\u00E9 indikace na prakticky v\u0161echny v\u011Bkov\u00E9 kategorie a potvrzen\u00ED \u00FA\u010Dinnosti v prevenci pneumoni\u00ED." . "5"^^ . . . "G44" . "14" . "Pneumococcal infections can still be considered severe illnesses in both pediatric and adult patients. Despite available vaccination, at-risk groups are still the most endangered ones. In some countries, an indirect effect of childhood vaccinations in the sense of decreasing incidence of invasive pneumococcal infections in adults is observed while this effect is absent in at-risk groups and immunocompromised patients. This indirect effect has not been described in the Czech republic yet; thus, the vaccination of the elderly and immunosuppressed or comorbid patients is of great importance here. Two types of vaccine are available - conjugated 13-valent and polysaccharide 23-valent. Each has its advantages and drawbacks. One approach to increasing the vaccination rate is represented by development of national recommendations for vaccinating physicians. Recommendation of the Czech Vaccinological Society was developed for this reason, concerning both vaccines. Full use of vaccination with the conjugated antipneumococcal vaccine in the at-risk groups can be expected after broadening the age-dependent indication to practically all age categories and after the effectiveness of vaccination in prophylaxis of pneumonia is confirmed."@en . "I" . "[A84E14E0F896]" . . "93179" . . "http://www.tribune.cz/tituly/mpp/archiv/499" . .